KRAS mutation and alterations in CDKN2A are early events in pancreatic tumorigenesis.[27] What’s more, tumor mutation burden was also a significant factor for both DSS and OS in PAAD.[28]. This evidence concerns the gene KRAS and pancreatic adenocarcinoma.